Discussions that mention norvasc

High & Low Blood Pressure board


I agree.. I sometimes feel a bit tired and (a little out out of it)and I'm only taking 10mg. My doctor was very much aware that Benicar is a much more potent ARB, and is proven with once a day dosing to reduce blood pressure for 24 hours (pretty consistently). It has to be potent......

10 mg of Benicar is more potent than 50 mg of atenolol and more potent than various doses of Norvasc and Capoten..

The lowest prescribed dosage is 5 mg. Tablets are 5, 20 and 40. I split my 20 mg tab in half. (This is also cost effective) It appears almost any dose will lower blood pressure.

These are a few articles I found on PubMed:

Olmesartan medoxomil is a new angiotensin II receptor blocker. In this randomized, double-blind, placebo-controlled study, the efficacy and safety of olmesartan medoxomil was assessed in 334 patients with moderate to severe essential hypertension. Patients were randomized to receive placebo; 5, 20, or 80 mg olmesartan medoxomil q.d.; or 2.5, 10, or 40 mg olmesartan medoxomil b.i.d. Ambulatory and cuff blood pressure were measured prior to and after 8 weeks of treatment. Treatment with olmesartan medoxomil resulted in a significant placebo-adjusted reduction of mean 24-hour ambulatory diastolic blood pressure of 9.6 mm Hg, 12.2 mm Hg, and 10.6 mm Hg in the 5-, 20-, and 80-mg q.d. groups, respectively. Corresponding reductions in mean ambulatory systolic blood pressure were 14.5 mm Hg, 16.5 mm Hg, and 15.4 mm Hg. Similar reductions of diastolic and systolic blood pressure were seen with b.i.d. dosing. The diastolic trough-to-peak ratios of the q.d. doses of olmesartan medoxomil ranged from 57%-70%, indicating 24-hour effectiveness. The safety profile of olmesartan medoxomil was similar to that of placebo. Olmesartan medoxomil appears to be a safe and effective once-a-day treatment for hypertension. Copyright 2002 Le Jacq Communications, Inc.

PMID: 12368570 [PubMed - indexed for MEDLINE]

This article shows the 10 mg strength:

OBJECTIVE: To compare the relative efficacy and safety of olmesartan medoxomil (OM) with atenolol, captopril and losartan in phase III trials on mild to severely hypertensive patients. DESIGN: Multi-centre, randomized, double-blind, parallel group, with dose-titration studies lasting 12 or 24 weeks. METHODS: Two studies respectively compared 10 mg OM once daily (o.d.) with: (1) 50 mg atenolol o.d. in moderate to severe hypertensives receiving 25 mg hydrochlorothiazide o.d. over 12 weeks; and (2) 50 mg losartan o.d. in mild to moderate hypertensives over 24 weeks, both with dose doubling at week4 if required. Study 3 compared 5 mg OM o.d. plus placebo o.d.with 12.5 mg captopril twice daily in mild to moderate hypertensives over 12 weeks, with dose doubling at weeks 4 and 8 if required. The primary outcome measure for all studies was the change from baseline to week 12 in trough mean sitting diastolic blood pressure (DBP). Safety was monitored throughout all studies. RESULTS: (1) Atenolol and OM both reduced BP effectively in moderate to severe hypertensives. OM was significantly superior to: (2) losartan (95% confidence interval for baseline to week 12 change in DBP < 0, lower limit < -3.6 mmHg); and (3) captopril (95% confidence interval for baseline to week 12 change in DBP < 0, lower limit < -4.8 mmHg) in BP reduction for mild to moderate hypertensives. Treatment with OM was safe and well tolerated. CONCLUSION: At the doses tested, olmesartan medoxomil o.d. is as effective as atenolol, and more effective than both losartan and captopril in reducing blood pressure in the hypertensive population.

PMID: 11451215 [PubMed - indexed for MEDLINE]

I hope this info helps